under the control of a baculovirus promoter so that the cells express GFP when they are infected with the virus. The baculovirus titer can then be quantitated from the level of GFP expression in the insect host cell. The results are obtained within 3 days compared to the 7–8 day period typical of the traditional CPE based methods.

The GFP based system is capable of replacing the traditional methods as it is faster, more accurate and may be less expensive than the currently used systems. This proprietary technology can become an indispensible tool for the quantitation of baculovirus titers; a step that is important in the production of recombinant proteins and vaccine like particles (VLPs) for academic and commercial purposes.

Applications: Baculovirus based recombinant protein expression.

Advantages: Fast, accurate, and inexpensive determination of baculovirus titers for protein expressi

baculovirus titers for protein expression. Inventors: Ralph F. Hopkins III and Dominic Esposito (SAIC/NCI).

Patent Status: U.S. Provisional Application No. 61/019,562 filed 07 Jan 2008 (HHS Reference No. E–009–2008/

0–US–01). *Licensing Status:* Available for

exclusive or non-exclusive licensing. Licensing Contact: Jasbir (Jesse) S. Kindra, J.D., M.S.; 301–435–5170; kindraj@mail.nih.gov.

A Molecular Grading System for Ductal Carcinoma In Situ (DCIS) of the Breast: A New Molecular Diagnostic To Determine Disease Stages of DCIS

Description of Technology: The technology describes the comprehensive profiling of Ductal Carcinoma in situ (DCIS) in breast cancer patients. The inventors have developed a molecular grading system for DCIS utilizing both gene expression profiling and genomic change profiling. The inventors have identified molecular profiles that identify early stage patients at risk of disease progression requiring more aggressive therapy. These observations suggest that a clinical assay could be developed for the grading of DCIS. Furthermore, the invention demonstrates that the profiles correlate with the molecular grade and with cell proliferation, suggesting that a clinical assay using routine methods, based on the nuclear grade and staining for Ki67 as a measure of proliferation, could also potentially be developed.

Advantages and Applications: The technology has the potential of being developed into an accurate diagnostic test for DCIS patients according to their risk of tumor progression. The diagnostic profiling can assist physicians in making clinically informed and personalized therapy decisions for DCIS patients.

In the studies, tissue samples collected via laser capture microdissection from in situ breast cancer patients were used, which validate and authenticate the relevance of the study.

Development Status: Larger clinical study is currently being planned.

Inventors: Paul S. Meltzer et al. (NCI). Patent Status: U.S. Provisional

Application No. 60/936,526 filed 20 Jun 2007 (HHS Reference No. E–192–2007/ 0–US–01).

Licensing Status: Available for exclusive and non-exclusive licensing.

Licensing Contact: Mojdeh Bahar, J.D.; 301–435–2950; baharm@mail.nih.gov.

Collaborative Research Opportunity: The National Cancer Institute, Genetics Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize molecular grading of DCIS. Please contact John D. Hewes, Ph.D. at 301–435–3121 or *hewesj@mail.nih.gov* for more information.

April 24, 2008.

David Sadowski,

Deputy Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E8–9535 Filed 4–30–08; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* National Institute of Dental and Craniofacial Research Special Emphasis Panel.

Date: June 19, 2008.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

^{Place:} National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Sooyoun (Sonia) Kim, MS, Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NIDCR/NIH, 6701 Democracy Blvd, Rm 675, Bethesda, MD 20892–4878, (301) 594–4827, *kims@email.nidr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: April 23, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–9404 Filed 4–30–08; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary

Public Workshop: Privacy Compliance Fundamentals—PTAs, PIAs, and SORNs

AGENCY: Privacy Office, Department of Homeland Security (DHS).

ACTION: Notice announcing public workshop.

SUMMARY: The Department of Homeland Security Privacy Office will host a public workshop, "Privacy Compliance Fundamentals—PTAs, PIAs, and SORNs."

DATES: The workshop will be held on May 23, 2008, from 9 a.m. to 4:30 p.m.

ADDRESSES: The workshop will be held in the auditorium at the DHS Offices at the GSA Regional Headquarters Building located at 7th and D Streets, SW., Washington, DC, 20024.

FOR FURTHER INFORMATION CONTACT:

Tamara Baker, Privacy Office, Department of Homeland Security, Washington, DC 20528; by telephone 703–235–0780; by facsimile 703–235– 0442; or by e-mail at *privacyworkshop@dhs.gov.*

SUPPLEMENTARY INFORMATION: The Department of Homeland Security (DHS) Privacy Office is holding a public workshop that will provide in-depth training on the privacy compliance process at DHS, and specifically how to write privacy impact assessments (PIAs)